GlassScriptPhysician profile
Cameron T French
NPI 1841289469
$5,069.99
in general payments reported to CMS, 2019-2025
19 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $1,005 · 2023: $1,012 · 2024: $1,455 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.23 |
| Education | $175.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,070.77 | 2021-2025 | |
| Janssen Biotech, INC. | $587.44 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $434.76 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $378.94 | 2021-2024 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $362.02 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $246.24 | 2022-2025 | Sotyktu |
| Ucb, INC. | $159.85 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $146.68 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $119.47 | 2021-2024 | Dupixent |
| Galderma Laboratories, L.P. | $92.12 | 2021-2025 | Nemluvio |
| Biofrontera INC. | $85.52 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $79.22 | 2022-2023 | Otezla |
| Organon LLC | $75.34 | 2025 | Vtama |
| Incyte Corporation | $71.95 | 2022-2024 | Opzelura |
| Genzyme Corporation | $41.72 | 2021-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $39.89 | 2023-2024 | Zoryve |
| Pfizer INC. | $34.64 | 2022-2025 | |
| Organogenesis INC. | $23.09 | 2024 | Puraply Am |
| Sanofi-Aventis U.S. LLC | $20.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron French listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.